Skip to main content

Advertisement

SpringerLink
Log in

Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Acute lymphoblastic leukemia of T cell lineage (T-ALL) is an aggressive malignant disease which accounts for 15 % of childhood ALL. T(11;14) is the more frequent chromosomal abnormality in childhood T-ALL, but its prognostic value remained controversial. Our aim was to analyze the outcome of childhood T-ALL with t(11;14) to know if the presence of this translocation is associated with a poor prognosis. We conducted a retrospective study from a series of 20 patients with t(11;14), treated in two consecutive trials from the European Organization for Research and Treatment of Cancer Children Leukemia Group over a 19-year period from 1989 to 2008. There were no significant differences between the 2 consecutive groups of patients with t(11;14) regarding the clinical and biological features at diagnosis. Among 19 patients who reached complete remission, 9 patients relapsed. We noticed 7 deaths all relapse- or failure-related. In the 58881 study, a presence of t(11;14) was associated with a poor outcome with an event-free survival at 5 years at 22.2 % versus 65.1 % for the non-t(11;14) T-ALL (p = 0.0004). In the more recent protocol, the outcome of T-ALL with t(11;14) reached that of non-t(11;14) T-ALL with an event-free survival at 5 years at 65.5 versus 74.9 % (p = 0.93). The presence of t(11;14) appeared as a poor prognostic feature in the 58881 trial whereas this abnormality no longer affected the outcome in the 58951 study. This difference is probably explained by the more intensive chemotherapy in the latest trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pui C-H, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350(15):1535–1548

    Article  PubMed  CAS  Google Scholar 

  2. Armstrong SA, Look AT (2005) Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 23(26):6306–6315

    Article  PubMed  CAS  Google Scholar 

  3. Kraszewska MD, Dawidowska M, Szczepański T, Witt M (2012) T-cell acute lymphoblastic leukaemia: recent molecular biology findings. Br J Haematol 156(3):303–315

    Article  PubMed  CAS  Google Scholar 

  4. Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG et al (1998) Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children’s Cancer Group. J Clin Oncol 16(4):1270–1278

    PubMed  CAS  Google Scholar 

  5. Raimondi SC, Behm FG, Roberson PK, Pui CH, Rivera GK, Murphy SB et al (1988) Cytogenetics of childhood T-cell leukemia. Blood 72(5):1560–1566

    PubMed  CAS  Google Scholar 

  6. Ribeiro RC, Raimondi SC, Behm FG, Cherrie J, Crist WM, Pui CH (1991) Clinical and biologic features of childhood T-cell leukemia with the t(11;14). Blood 78(2):466–470

    PubMed  CAS  Google Scholar 

  7. Schneider NR, Carroll AJ, Shuster JJ, Pullen DJ, Link MP, Borowitz MJ et al (2000) New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. Blood 96(7):2543–2549

    PubMed  CAS  Google Scholar 

  8. Groupe Français de Cytogénétique Hématologique (1993) Collaborative study of karyotypes in childhood acute lymphoblastic leukemias. Leukemia 7(1):10–19

    Google Scholar 

  9. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH (1991) The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A 88(10):4367–4371

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. McGuire EA, Hockett RD, Pollock KM, Bartholdi MF, O’Brien SJ, Korsmeyer SJ (1989) The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell Biol 9(5):2124–2132

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Sánchez-García I, Rabbitts TH (1993) LIM domain proteins in leukaemia and development. Semin Cancer Biol 4(6):349–358

    PubMed  Google Scholar 

  12. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9(10):1783–1786

    PubMed  CAS  Google Scholar 

  13. Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G et al (2010) NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 24(12):2023–2031

    Article  PubMed  CAS  Google Scholar 

  14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481

    Article  Google Scholar 

  15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35(1):1–39

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Uckun FM, Gajl-Peczalska KJ, Provisor AJ, Heerema NA (1989) Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. Blood 73(1):271–280

    PubMed  CAS  Google Scholar 

  17. Zalcberg IQ, Silva ML, Abdelhay E, Tabak DG, Ornellas MH, Simões FV et al (1995) Translocation 11;14 in three children with acute lymphoblastic leukemia of T-cell origin. Cancer Genet Cytogenet 84(1):32–38

    Article  PubMed  CAS  Google Scholar 

  18. Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG et al (1997) Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children’s Cancer Group study. J Clin Oncol 15(6):2214–2221

    PubMed  CAS  Google Scholar 

  19. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10(2):147–156

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez-Irizarry C et al (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306(5694):269–271

    Article  PubMed  CAS  Google Scholar 

  21. Cavé H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al (2004) Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 103(2):442–450

    Article  PubMed  Google Scholar 

  22. Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, Soler G et al (2007) Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood 110(7):2324–2330

    Article  PubMed  CAS  Google Scholar 

  23. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH et al (2004) Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 363(9408):535–536

    Article  PubMed  CAS  Google Scholar 

  24. Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L et al (2010) Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24(2):320–334

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M et al (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13(3):335–342

    Article  PubMed  CAS  Google Scholar 

  26. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al (2002) Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trial. Blood 99(8):2734–2739

    Article  PubMed  CAS  Google Scholar 

  27. McNeer JL, Nachman JB (2010) The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol 149(5):638–652

    Article  PubMed  CAS  Google Scholar 

  28. Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C et al (1991) Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19(4):269–275

    Article  PubMed  CAS  Google Scholar 

  29. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TOB (2005) Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129(6):734–745

    Article  PubMed  CAS  Google Scholar 

  30. Schrappe M, Zimmerman M, Moricke A, Mann G, Valsecchi MG, Bartram CR et al (2008) Dexamethasone in induction can eliminate one-third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomised trial in 3655 patients (trial AIEOP-BFM ALL 2000). ASH Annu Meeting Abstr 112(11):7

    Google Scholar 

  31. Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y et al (2005) No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children’s Cancer Study Group L95-14 protocol. J Clin Oncol 23(27):6489–6498

    Article  PubMed  CAS  Google Scholar 

  32. Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN et al (1998) Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children’s Cancer Group. J Clin Oncol 16(3):920–930

    PubMed  CAS  Google Scholar 

  33. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R et al (2011) Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood 118(4):874–883

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  34. Szczepanski T, van der Velden VHJ, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B et al (2011) Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol 29(12):1643–1649

    Article  PubMed  CAS  Google Scholar 

  35. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med 339(9):591–598

    Article  PubMed  Google Scholar 

  36. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A et al (2011) Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 118(8):2077–2084

    Article  PubMed  CAS  Google Scholar 

  37. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B et al (2006) Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 24(36):5742–5749

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the EORTC-CLG study group members for their participation in the study; a complete list of the participating institutions and investigators appears in the Appendix. The authors would like to thank the EORTC HQ Data Management Department members (Séraphine Rosse, Lies Meirlaen, Liv Meert, Aurélie Dubois, Christine Waterkeyn, Alessandra Busato, Isabel VandeVelde, and Gabriel Solbu) for their support of this trial. This study was supported by the EORTC Charitable Trust Foundation; Vlaamse Liga Tegen Kanker, Belgian Federation Against Cancer, non-profit organization; and TéléVie and Kinderkankerfonds from Belgium.

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology-Oncology, CHU, Besançon, France

    Pauline Simon, Emmanuel Plouvier & Pierre S. Rohrlich

  2. EORTC Headquarters, Brussels, Belgium

    Stefan Suciu

  3. Department of Hemato-Immunology, Robert Debré Hospital, Paris, France

    Emmanuelle Clappier & Hélène Cave

  4. Department of Pediatric Hematology-Oncology, University Hospital Lapeyronie, Montpellier, France

    Nicolas Sirvent

  5. Department of Hematology, Children’s Hospital, Toulouse, France

    Geneviève Plat

  6. Centre Antoine Lacassagne, Nice, France

    Antoine Thyss

  7. Department of Pediatric Hematology-Oncology, CHR, Nantes, France

    Françoise Mechinaud

  8. Department of Pediatrics, Escolar San Joao Hospital, Porto, Portugal

    Vitor M. Costa

  9. Department of Hemato-Oncology, HUDE, Brussels, Belgium

    Alina Ferster

  10. Department of Hematology, Hautepierre, Strasbourg, France

    Patrick Lutz

  11. Department of Pediatric Hematology-Oncology, CHR, Lille, France

    Françoise Mazingue

  12. Department of Pediatrics, CHR La Tronche, Grenoble, France

    Dominique Plantaz

  13. Institut of Pediatric Hematology-Oncology (IHOP), Lyon, France

    Yves Bertrand

  14. Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium

    Yves Benoit

  15. Laboratory of Cytogenetics, University Hospital, Toulouse, France

    Nicole Dastugue

Authors
  1. Pauline Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Suciu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emmanuelle Clappier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hélène Cave
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicolas Sirvent
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Geneviève Plat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antoine Thyss
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Françoise Mechinaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vitor M. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alina Ferster
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Patrick Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Françoise Mazingue
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Dominique Plantaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Emmanuel Plouvier
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yves Bertrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Yves Benoit
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Nicole Dastugue
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Pierre S. Rohrlich
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC)

Corresponding author

Correspondence to Pierre S. Rohrlich.

Ethics declarations

Informed consent was provided according to the Declaration of Helsinki. These protocols have been accepted by the EORTC Protocol Review Committee and by the ethics committee of each participating center.

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 40 kb)

Appendix

Appendix

Information about the contributions of each person named as having participated in the study

  1. 1.

    Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:

    • Pauline Simon, Department of Pediatric Hematology-Oncology, CHU, Besançon, France; p1simon@chu-besancon.fr

    • Pierre S Rohrlich, Department of Pediatric Hematology-Oncology, CHU, Nice, France; rohrlich.ps@chu-nice.fr

    • Nicole Dastugue, Laboratory of Cytogenetics, University Hospital, Toulouse, France

    • Stefan Suciu, EORTC Headquarters, Brussels, Belgium, stefan.suciu@eortc.be

    The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

  2. 2.

    Authors who participated in the conception of the study: Pauline SIMON, Pierre S Rohrlich, Stefan Suciu, and Nicole Dastugue

  3. 3.

    Design and methods. The following authors were responsible for specific investigations:

    • Yves Bertrand, Yves Benoit, Stefan Suciu, and Hélène Cavé developed the study design.

    • Nicolas Sirvent, Geneviève Plat, Antoine Thyss, Françoise Mechinaud, Vitor M Costa, Alina Ferster, Patrick Lutz, Françoise Mazingue, Dominique Plantaz, Emmanuel Plouvier, Yves Bertrand, Yves Benoit, and Pierre S Rohrlich were involved in the acquisition of clinical data.

    • Emmanuelle Clappier and Hélène Cave were responsible for molecular data.

    • Nicole Dastugue was responsible for the cytogenetics.

    • Stefan Suciu developed the analytical approach to the data.

  4. 4.

    Results. The following authors were responsible for specific portions of the results, including figures and tables:

    • Pauline Simon, Pierre S. Rohrlich, and Stefan Suciu were involved in the analysis and/or interpretation of data.

    • Stefan Suciu performed the statistical analyses.

    • Pauline Simon, Pierre S. Rohrlich, Stefan Suciu, and Nicole Dastugue prepared and are responsible for all figures and tables.

  5. 5.

    Writing the manuscript. The following authors were responsible for writing the manuscript:

    • Pauline Simon, Pierre S. Rohrlich, and Nicole Dastugue drafted the manuscript.

    • Emmanuelle Clappier, Hélène Cavé, Alina Ferster, Yves Bertrand, Yves Benoit, and Nicole Dastugue critically evaluated the manuscript and actively improved its scientific value.

    • Stefan Suciu, Emmanuelle Clappier, Hélène Cavé, Nicolas Sirvent, Geneviève Plat, Antoine Thyss, Françoise Mechinaud, Vitor M. Costa, Alina Ferster, Patrick Lutz, Françoise Mazingue, Dominique Plantaz, Emmanuel Plouvier, Yves Bertrand, Yves Benoit, and Nicole Dastugue approved the final version of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Simon, P., Suciu, S., Clappier, E. et al. Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials. Ann Hematol 95, 93–103 (2016). https://doi.org/10.1007/s00277-015-2515-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2515-8

Keywords

Search

Navigation